Thursday, Vor Biopharma Inc. (NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg. Pfizer Inc’s (NYSE:PFE) Mylotarg is indicated for newly diagnosed CD33-positive AML in adults and relapsed or refractory AML CD33-positive acute myeloid leukemia in adults and pediatric patients two years and older. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit….